Health ❯Healthcare ❯Clinical Trials ❯Efficacy Studies

Lecanemab

France Blocks Early Access to Alzheimer’s Drug Leqembi for Now

The health regulator says the trial benefit is too small to justify early availability.

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs